scholarly journals Fixed-Dose Combination of Dipeptidyl Peptidase-4 Inhibitors Plus Metformin in Patients with Type 2 Diabetes: A Review on Safety and Efficacy

2021 ◽  
pp. 53-59
Author(s):  
Sultan M. Alshahrani ◽  
Hamed Ali Alshahrani ◽  
Saud Dhafer Alshahrani ◽  
Noura Mohammed Alabdulla ◽  
Yazeed Fahad Alshahrani ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
International Diabetes Federation ◽  
Dipeptidyl Peptidase ◽  
Fixed Dose ◽  
Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Agents ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Fixed Drug

There is a significant increase noted in the incidence and prevalence of Type 2 diabetes mellitus (T2DM). The global number of diabetic patients is projected by the International Diabetes Federation (IDF) to reach 552 million. T2DM disease has chronic and progressive nature. More than fifty percent of patients do not attain adequate glycemic control despite initial sufficient monotherapy. To maintain target glycated hemoglobin (HbA1c) levels (<7%), dose adjustment and adoption of several diabetes therapies become necessary in many cases. Compared to monotherapy, a fixed drug combination of oral agents and metformin has proven to be more efficacious to maintain levels of blood glucose and HbA1c. The combination of dipeptidyl peptidase-4 inhibitors (DDPIs) and metformin has been explicated to effectively decrease HbA1c to a relatively higher degree compared to the use of either agent individually. This combination addresses various pathophysiological processes involved in T2DM pathogenesis. Additionally, the concerned combination is safe and associated with a lower risk of hypoglycemia. Moreover, it is well-tolerated and prescribed as an easy-to-use single pill to improve patient compliance. This review provides an overview of the pharmacology, efficacy, and safety of fixed drug combinations of DDPIs and metformin according to current practice.

Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs

2011 ◽  
Vol 152 (37) ◽  
pp. 1471-1476 ◽  
Author(s):  
György Jermendy
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Antidiabetic Drugs ◽  
Dose Titration ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Antidiabetic ◽  
Dipeptidyl Peptidase 4 Inhibitors

Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin. Orv. Hetil., 2011, 152, 1471–1476.

scholarly journals SAT0583 DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1250.2-1251
Author(s):  
W. S. Chen ◽  
Y. S. Chang ◽  
C. Y. Tsai ◽  
C. C. Chang
Keyword(s):  
Type 2 Diabetes ◽  
Propensity Score ◽  
Combination Therapy ◽  
Group Versus ◽  
Dipeptidyl Peptidase ◽  
Matched Pair ◽  
Diabetic Patients ◽  
Research Database ◽  
Dipeptidyl Peptidase 4

Background:The risk of psoriasis in diabetic patients has rarely been explored.Objectives:This study aimed to investigate the association between dipeptidyl peptidase-4 (DPP4) inhibitors and the risk of psoriasis in type 2 diabetes mellitus (T2DM) patients.Methods:We conducted a population-based propensity score-matched cohort study on the basis of Taiwan’s National Health Insurance Research Database that included initiators of combination therapy with DPP4i (DPP4i plus metformin) and sulfonylurea (sulfonylurea plus metformin). Psoriasis (PSO) was identified with ≥2 diagnoses. Diabetes complications severity index (DCSI) was calculated. A total of 22721 DPP4 initiator and 227684 sulfonylurea initiator were identified. A 1:10 matched-pair cohort based on propensity score(PS) was created. PS-stratified Cox proportional hazards models compared the risk of PSO in DPP4i versus sulfonylurea initiator within 2 years, controlling for potential confounders.Results:After propensity score matching, 9962 patients with T2DM starting DPP4i combination therapy and 39848 starting sulfonylurea combination therapy were selected. The incidence rate of PSO was lower in DPP4i group (188/100000 person- years) than in sulfonylurea group (467/100000 person-years). Risks of incident psoriasis were significantly lower in the DPP4i group versus sulfonylurea with the PS-stratified HR of 0.422 (95% CI 0.273 to 0.716).Conclusion:DPP4i plus metformin was associated with a reduced risk of psoriasis than sulfonylurea plus metformin. These findings merit further investigation.Disclosure of Interests:None declared

scholarly journals Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

2014 ◽  
Vol 51 (6) ◽  
pp. 1015-1023 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Robert J. Glynn ◽  
Jun Liu ◽  
Brendan M. Everett ◽  
Allison B. Goldfine
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Cardiovascular Events ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document